We represented a national pharmaceutical ingredient supplier and its wholly owned subsidiaries in a Department of Justice investigation involving allegations of False Claims Act violations related to inflated Average Wholesale Prices, kickbacks to physicians, and waivers of co-pay obligations. Following a multi-year investigation arising from four separate qui tam actions, we negotiated a successful resolution of the matter that was substantially less than the government’s alleged damages.